Fundraising Fox

Odyssey Therapeutics

Cambridge, US · Founded 2021 · 13 known investors

odysseytx.com ↗

Creating next generation precision medicines for patients with cancer and inflammatory diseases by targeting key signaling nodes.

Biotechin /odyssey-tx@odyssey_tx

Founders & leadership

VO
Valerie OdegardDirector
JC
Jill CarrollDirector
CG
Carl GordonDirector
JL
Jeffrey LeidenDirector
CB
Charles BaumDirector
GD
Gary D GlickExecutive Officer, Director

Investors · 13

Activant CapitalNew York · $100K – $50M
Balderton CapitalLondon · $5M – $50M
Catalio Capital Management, LPNew York
Foresite CapitalLarkspur
Global BioAccess FundNew York · $10M
GreatPoint VenturesSan Francisco · $250K – $20M
Jeito CapitalParis
Lightspeed Venture PartnersMenlo Park · $1.7M – $87M
OrbiMedNew York · $1M – $75M
Sanofi VenturesCambridge · $5M
SR One Capital ManagementRedwood Cityvia Jill Carroll · board
Ascenta CapitalreportedWilmington
Dimension Capitalreported · 2 sourcesSan Francisco · $1M – $10M

Reported raises · per SEC filings

Form D private placements
▶$214MraisedDec 2025 · 55 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Valerie OdegardDirector
  • Carl GordonDirector
  • Carolyn NgDirector
  • Gary D. GlickExecutive Officer, Director
  • Timothy WalbertDirector
  • Paulina HillDirector
  • Nan LiDirector
  • Jeffrey LeidenDirector
  • Jason HaasExecutive Officer
  • Nia TatsisDirector
  • Ksenija PavleticDirector
  • Shelley ChuDirector
  • lan F. SmithDirector
  • Jill CarrollDirector
Offering amount
$214M
Amount sold
$214M
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$117.2MraisedAug 2024 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy WalbertDirector
  • Charles M. BaumDirector
  • Gary D. GlickExecutive Officer, Director
  • Jill CarrollDirector
  • Jeffrey LeidenDirector
  • Ian SmithDirector
  • Valerie OdegardDirector
  • Lorence KimDirector
  • Carl GordonDirector
Offering amount
$121.1M
Amount sold
$117.2M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$168MraisedOct 2022 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Valerie OdegardDirector
  • Jill CarrollDirector
  • Carl GordonDirector
  • Jeffrey LeidenDirector
  • Charles BaumDirector
  • Gary D GlickExecutive Officer, Director
Offering amount
$174.9M
Amount sold
$168M
First sale
May 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$91.6MraisedOct 2021 · 63 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carl GordonDirector
  • Chuck BaumDirector
  • Valerie OdegardDirector
  • Gary D GlickExecutive Officer, Director
  • Jill CarrollDirector
Amount sold
$91.6M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.